AHA Scientific Sessions 2023
Phase 1 data show sustained Lp(a) reduction with lepodisiran
A single dose of the short interfering RNA, lepodisiran (608 mg s.c.) reduced serum Lp(a) by 94% at 48 weeks follow up in a Phase 1 dose ranging study.1 Lepodisiran, which targets hepatic synthesis of apolipoprotein(a), a key component needed for assembly of Lp(a) particles,…
read more »
Heart-1 trial: Interim data show PCSK9 gene editing lowers LDL-C
VERVE-101, a CRISPR-based gene editing therapy, significantly reduces LDL-C in patients with HeFH and established atherosclerotic cardiovascular disease (ASCVD), according to interim results from the ongoing Phase 1b, heart-1 study (NCT05398029). The heart-1 trial is designed to evaluate the safety and tolerability of VERVE-101, with…
read more »
Small apoA isoforms linked to worse PAD revascularisation outcomes
Small apo(a) isoform expression could be an important risk predictor of worse short term surgical outcomes after lower extremity revascularisation.1 This is the conclusion of researchers who related apoA size to revascularisation outcomes in 25 patients with symptomatic peripheral arterial disease (PAD). Most patients had…
read more »
OCEAN(a)-DOSE study highlights Lp(a) variability with time
Changes in Lp(a) level over time, recorded in placebo-treated individuals in the Phase 2 OCEAN(a)-DOSE trial, suggest that once-in-a-lifetime measurement of Lp(a) may not be sufficient for identifying at-risk individuals in need of treatment.1 Current American College of Cardiology (ACC) guidelines recommend once-in-a-lifetime Lp(a) measurement,2…
read more »
EBBINGHAUS study reassures about cognitive safety with long-term PCSK9 inhibition
No apparent long-term decline in cognitive function linked to evolocumab has been found in over seven years of follow up in EBBINGHAUS, a prespecified substudy within the FOURIER trial. Of 1204 patients from EBBINGHAUS, 306 entered the open label extension (OLE) and were treated with…
read more »
